- Ibuprofen
- Aspirin
- Paracetmol
- Diclofenac
- Others
NSAIDs API Market size was valued at USD x million in 2022 and is poised to grow at a CAGR of x% from 2023-2029. owing to increase in prevalence of arthritis, which is the major cause for the disability and growing number of geriatric population across the globe drives the growth of the market. For instance, According to Center for Disease Control and Prevention (CDC), from 2013-2015, approximately 54.4 Mn US adults had some form of arthritis such as gout, rheumatoid arthritis treatment, fibromyalgia, and lupus and estimated to reach 78 Mn adults aged 18 years older are projected to have arthritis by 2040.  NSAIDs are drug class that groups together drugs that provide analgesic and anti-pyretic effects. Moreover, increasing access to healthcare with the rapid penetration of technology and other developments in the healthcare sector has increased the consumption of drugs, thereby directly creating positive impact on NSAID market. However, availability of alternative products in the market for NSAIDs and development of advanced medications are expected to hamper the growth of the market. This report studies Global NSAIDs API market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, Global NSAIDs API market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed Global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global NSAIDs API market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in Global NSAIDs API.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Low cost of the non-steroidal anti-inflammatory drugs such as ibuprofen, diclofenac, piroxicam, aspirin, and other drugs coupled with the better availability of the products boost the revenue growth of global NSAIDs market over the forecast years. Formulation of NSAIDs for the patient convenience also enhance the market revenue in the forthcoming years. For instance, Pfizer, Inc. marketing the Flector (Diclofenac Epolamine Topical Patch) to treat acute pain due to minor strains, sprains, and bruises. In addition, NSAIDs also available in the injectable forms which are easy to administer the patients unable to swallow the tablets. Moreover, Mylan laboratories manufacturing Brufen effervescent granules that can be easily administered for the geriatric and paediatric patients
The nsaids api market size was valued at USD x million in 2022
Increased the consumption of drugs
Asia Pacific is the fastest-growing for nsaids api market
1. Executive Summary |
2. Global Nsaids Api Market Introduction |
2.1.Global Nsaids Api Market - Taxonomy |
2.2.Global Nsaids Api Market - Definitions |
2.2.1.Molecule Type |
2.2.2.Formulation |
2.2.3.Region |
3. Global Nsaids Api Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Nsaids Api Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Nsaids Api Market By Molecule Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Ibuprofen |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Aspirin |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Paracetmol |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Diclofenac |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Global Nsaids Api Market By Formulation, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Tablets |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Capsules |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Suspension |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Topical Presentations |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7. Global Nsaids Api Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Nsaids Api Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Molecule Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Ibuprofen |
8.1.2.Aspirin |
8.1.3.Paracetmol |
8.1.4.Diclofenac |
8.1.5.Others |
8.2. Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Tablets |
8.2.2.Capsules |
8.2.3.Suspension |
8.2.4.Topical Presentations |
8.2.5.Others |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Nsaids Api Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Molecule Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Ibuprofen |
9.1.2.Aspirin |
9.1.3.Paracetmol |
9.1.4.Diclofenac |
9.1.5.Others |
9.2. Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Tablets |
9.2.2.Capsules |
9.2.3.Suspension |
9.2.4.Topical Presentations |
9.2.5.Others |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
9.3.7. |
10. Asia Pacific (APAC) Nsaids Api Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Molecule Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Ibuprofen |
10.1.2.Aspirin |
10.1.3.Paracetmol |
10.1.4.Diclofenac |
10.1.5.Others |
10.2. Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Tablets |
10.2.2.Capsules |
10.2.3.Suspension |
10.2.4.Topical Presentations |
10.2.5.Others |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Nsaids Api Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Molecule Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Ibuprofen |
11.1.2.Aspirin |
11.1.3.Paracetmol |
11.1.4.Diclofenac |
11.1.5.Others |
11.2. Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Tablets |
11.2.2.Capsules |
11.2.3.Suspension |
11.2.4.Topical Presentations |
11.2.5.Others |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Nsaids Api Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Molecule Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Ibuprofen |
12.1.2.Aspirin |
12.1.3.Paracetmol |
12.1.4.Diclofenac |
12.1.5.Others |
12.2. Formulation Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Tablets |
12.2.2.Capsules |
12.2.3.Suspension |
12.2.4.Topical Presentations |
12.2.5.Others |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Granules India Ltd. (India) |
13.2.2.Xinuha Pharm (China) |
13.2.3.IOL Chemicals and Pharmaceuticals Ld. (India) |
13.2.4.Strides Pharma Science Limited (India) |
13.2.5.SI Group (U.S.) |
13.2.6.BASF SE (Germany) |
13.2.7.Bayer AG (Germany) |
13.2.8.Pfizer, Inc. (U.S.) |
14. Research Methodology |
15. Appendix and Abbreviations |